Surmodics (SRDX) Competitors $31.81 -0.56 (-1.73%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRDX vs. ATRC, IART, OFIX, ANGO, ARAY, RMTI, RSLS, ABT, ISRG, and BSXShould you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include AtriCure (ATRC), Integra LifeSciences (IART), Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), and Boston Scientific (BSX). These companies are all part of the "health care equipment" industry. Surmodics vs. Its Competitors AtriCure Integra LifeSciences Orthofix Medical AngioDynamics Accuray Rockwell Medical ReShape Lifesciences Abbott Laboratories Intuitive Surgical Boston Scientific AtriCure (NASDAQ:ATRC) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Which has stronger earnings and valuation, ATRC or SRDX? Surmodics has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtriCure$465.31M3.84-$44.70M-$0.77-46.66Surmodics$120.80M3.77-$11.54M-$1.23-25.86 Do insiders and institutionals have more ownership in ATRC or SRDX? 99.1% of AtriCure shares are owned by institutional investors. Comparatively, 96.6% of Surmodics shares are owned by institutional investors. 3.5% of AtriCure shares are owned by insiders. Comparatively, 8.9% of Surmodics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ATRC or SRDX more profitable? AtriCure has a net margin of -7.27% compared to Surmodics' net margin of -14.59%. Surmodics' return on equity of -2.99% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets AtriCure-7.27% -4.20% -3.19% Surmodics -14.59%-2.99%-1.99% Do analysts rate ATRC or SRDX? AtriCure presently has a consensus price target of $50.89, indicating a potential upside of 41.65%. Surmodics has a consensus price target of $43.00, indicating a potential upside of 35.18%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Surmodics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AtriCure 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Surmodics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility and risk, ATRC or SRDX? AtriCure has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Does the media refer more to ATRC or SRDX? In the previous week, AtriCure had 10 more articles in the media than Surmodics. MarketBeat recorded 13 mentions for AtriCure and 3 mentions for Surmodics. Surmodics' average media sentiment score of 1.77 beat AtriCure's score of 0.83 indicating that Surmodics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Surmodics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryAtriCure beats Surmodics on 10 of the 16 factors compared between the two stocks. Get Surmodics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRDX vs. The Competition Export to ExcelMetricSurmodicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$454.82M$10.62B$5.70B$10.27BDividend YieldN/A1.86%5.72%4.60%P/E Ratio-25.8621.4275.8126.51Price / Sales3.7730.40492.95166.26Price / Cash103.3025.0025.8129.90Price / Book3.823.4312.836.31Net Income-$11.54M$212.47M$3.28B$270.12M7 Day Performance-3.17%-0.85%0.24%2.04%1 Month Performance-15.08%2.29%4.59%6.25%1 Year Performance-19.35%-10.76%68.69%25.50% Surmodics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRDXSurmodics4.5532 of 5 stars$31.81-1.7%$43.00+35.2%-17.8%$454.82M$120.80M-25.86450Positive NewsATRCAtriCure2.5123 of 5 stars$36.00+1.8%$50.89+41.4%+22.8%$1.76B$499.95M-46.751,300News CoverageInsider TradeIARTIntegra LifeSciences3.7747 of 5 stars$15.68-1.9%$18.43+17.5%-13.7%$1.25B$1.61B-2.404,396Positive NewsOFIXOrthofix Medical3.4897 of 5 stars$14.70+1.0%$21.50+46.3%-12.0%$574.64M$799.49M-4.641,616Positive NewsANGOAngioDynamics4.1642 of 5 stars$10.90+1.6%$19.00+74.3%+37.4%$436M$292.50M-13.13760Positive NewsARAYAccuray4.7559 of 5 stars$1.55+2.6%$5.00+222.6%-26.5%$170.14M$458.51M-77.501,040Analyst UpgradeRMTIRockwell Medical3.798 of 5 stars$1.59-1.9%$4.00+151.6%-57.2%$55.78M$87.97M-26.50300Gap UpRSLSReShape LifesciencesN/A$3.16-1.4%N/A-99.7%$8.49M$8.01M-0.0350Gap DownHigh Trading VolumeABTAbbott Laboratories4.913 of 5 stars$132.27-0.5%$144.47+9.2%+12.9%$231.38B$41.95B16.58114,000Positive NewsISRGIntuitive Surgical4.9481 of 5 stars$470.00+0.7%$595.95+26.8%-11.4%$167.36B$8.35B65.5515,638Trending NewsAnalyst RevisionBSXBoston Scientific4.8394 of 5 stars$108.14+0.9%$117.79+8.9%+19.7%$158.87B$16.75B64.3753,000Positive NewsOptions Volume Related Companies and Tools Related Companies AtriCure Competitors Integra LifeSciences Competitors Orthofix Medical Competitors AngioDynamics Competitors Accuray Competitors Rockwell Medical Competitors ReShape Lifesciences Competitors Abbott Laboratories Competitors Intuitive Surgical Competitors Boston Scientific Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRDX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRDX Stock Alerts